 |
|
Key protein regulating inflammation may prove relevant to controlling sepsis
May 15, 2009Singapore research pubished in Nature Cell Biology
Scientists at Singapore's Institute of Molecular and Cell Biology (IMCB), under the Agency for Science, Technology and Research (A*STAR), have identified the protein, WIP1, as the molecular "brake" that curbs severe inflammation in the body.
The findings may prove relevant to developing more effective treatments against sepsis, the severe inflammatory condition caused by bacterial infection that afflicts many patients in intensive care units (ICU).
In their paper, "WIP1 phosphatase is a negative regulator of NFκB signaling," published in the May 2009 issue of Nature Cell Biology (NCB), the IMCB scientists described their results showing the importance of WIP1 as an effective suppressor of inflammation and explained how the body was able to cope with an excess of inflammation brought on by the hyperactivation of the NFκB protein complex, a signaling molecule that plays a key role in triggering inflammation.
"We have shown that WIP1 plays a critical role in suppressing the activity of NFκB and keeping NFκB levels within a safe range," said IMCB principal investigator Vinay Tergaonkar, Ph.D., who headed the research team. "In doing so, WIP1 minimizes the extent of inflammatory response that could lead to septic shock and subsequent death of patients."
Dr. Tergaonkar and his colleagues compared the inflammatory response in mice lacking in WIP1 and in a control group of mice with normal WIP1 levels. The inflammatory response was higher in the WIP1 deficient animals. Correspondingly, the inflammatory response in mice with high WIP1 levels was suppressed.
In separate research, a second group of scientists led by Dr. Tergaonkar found further evidence linking chronic inflammation to the development of cancers such as that of the stomach and liver.
Dr. Tergaonkar and his colleagues discovered that the kinase enzyme IκB kinase 2 (IKK2), which is known for causing inflammation through the activation of NFκB, is also responsible for "ordering" the destruction of the tumour suppressor protein p53.
This discovery, published in the February 2009 issue of the Proceedings of the National Academy of Sciences (PNAS) and entitled, "Phosphorylation of p53 by IκB kinase 2 promotes its degradation by β-TrCP," provides fresh insight about how cells that have become inflamed due to exposure to high IKK2 activity, can become more susceptible to tumour development.
"Our recent discoveries have provided an explanation on the beneficial and harmful effects of inflammation that have baffled scientists for years," added Dr Tergaonkar. "While the natural inflammatory response serves to help the body clear infection, excessive inflammation, on the other hand, promotes cellular changes that lead to the uncontrolled growth of cells that characterizes cancer and enables its spread. These new insights involving NFκB, WIP1 and IKK2 are fostering new anti-inflammatory therapeutic approaches to human ailments ranging from inflammation (like sepsis) to cancer."
Shen Han-Ming, Ph.D., an expert in cancer cell biology at the National University of Singapore's Yong Loo Lin School of Medicine, said, "Taken together, the work in Dr Tergaonkar's lab has significantly advanced our understanding of the regulatory mechanisms of NFκB and expanded the functional scope of NFκB. More important, such findings offer new opportunities for modulation of the NFκB signaling pathway and for exploring new therapeutic strategies in various human diseases such as cancer and sepsis."
Agency for Science, Technology and Research (A*STAR), Singapore
In their paper, "WIP1 phosphatase is a negative regulator of NFκB signaling," published in the May 2009 issue of Nature Cell Biology (NCB), the IMCB scientists described their results showing the importance of WIP1 as an effective suppressor of inflammation and explained how the body was able to cope with an excess of inflammation brought on by the hyperactivation of the NFκB protein complex, a signaling molecule that plays a key role in triggering inflammation.
"We have shown that WIP1 plays a critical role in suppressing the activity of NFκB and keeping NFκB levels within a safe range," said IMCB principal investigator Vinay Tergaonkar, Ph.D., who headed the research team. "In doing so, WIP1 minimizes the extent of inflammatory response that could lead to septic shock and subsequent death of patients."
Dr. Tergaonkar and his colleagues compared the inflammatory response in mice lacking in WIP1 and in a control group of mice with normal WIP1 levels. The inflammatory response was higher in the WIP1 deficient animals. Correspondingly, the inflammatory response in mice with high WIP1 levels was suppressed.
In separate research, a second group of scientists led by Dr. Tergaonkar found further evidence linking chronic inflammation to the development of cancers such as that of the stomach and liver.
Dr. Tergaonkar and his colleagues discovered that the kinase enzyme IκB kinase 2 (IKK2), which is known for causing inflammation through the activation of NFκB, is also responsible for "ordering" the destruction of the tumour suppressor protein p53.
This discovery, published in the February 2009 issue of the Proceedings of the National Academy of Sciences (PNAS) and entitled, "Phosphorylation of p53 by IκB kinase 2 promotes its degradation by β-TrCP," provides fresh insight about how cells that have become inflamed due to exposure to high IKK2 activity, can become more susceptible to tumour development.
"Our recent discoveries have provided an explanation on the beneficial and harmful effects of inflammation that have baffled scientists for years," added Dr Tergaonkar. "While the natural inflammatory response serves to help the body clear infection, excessive inflammation, on the other hand, promotes cellular changes that lead to the uncontrolled growth of cells that characterizes cancer and enables its spread. These new insights involving NFκB, WIP1 and IKK2 are fostering new anti-inflammatory therapeutic approaches to human ailments ranging from inflammation (like sepsis) to cancer."
Shen Han-Ming, Ph.D., an expert in cancer cell biology at the National University of Singapore's Yong Loo Lin School of Medicine, said, "Taken together, the work in Dr Tergaonkar's lab has significantly advanced our understanding of the regulatory mechanisms of NFκB and expanded the functional scope of NFκB. More important, such findings offer new opportunities for modulation of the NFκB signaling pathway and for exploring new therapeutic strategies in various human diseases such as cancer and sepsis."
Agency for Science, Technology and Research (A*STAR), Singapore
Sepsis Current Events and Sepsis News RSSA Second Skin
Despite advances in treatment regimens and the best efforts of nurses and doctors, about 70% of all people with severe burns die from related infections.
Progress made on group B streptococcus vaccine
Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have completed a Phase II clinical study that indicates a vaccine to prevent Group B Streptococcus (GBS) infection is possible.
Canadian scientists link fat hormone to death from potentially deadly blood infection
A new Canadian study has found that lower-than-normal levels of a naturally-occurring fat hormone may increase the risk of death from sepsis-an overwhelming infection of the blood which claims thousands of lives each year.
OMRF scientists discover promising new path for treating traumas
A discovery by scientists at the Oklahoma Medical Research Foundation could help save lives threatened by traumatic injuries like those sustained in car crashes or on the battlefield. The work also holds potential for treating severe infectious diseases and diabetes.
Scientists create NICE solution to pneumonia vaccine testing problems
Medical clinics the world over could benefit from new software* created at the National Institute of Standards and Technology (NIST), where a team of scientists has found a way to improve the efficiency of a pneumonia vaccine testing method developed at the University of Alabama at Birmingham (UAB).
Compound shows potential for slowing progression of ALS
A chemical cousin of a drug currently used to treat sepsis dramatically slows the progression of amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig's disease, in mice.
Review: Pneumococcal conjugate vaccines effective at preventing child deaths
A study published in The Cochrane Review this month concludes that pneumococcal conjugate vaccines (PCV), already known to prevent invasive pneumococcal disease (IPD) and x-ray defined pneumonia, was also effective against child deaths.
Key feature of immune system survived in humans, other primates for 60 million years
A new study has concluded that one key part of the immune system, the ability of vitamin D to regulate anti-bactericidal proteins, is so important that is has been conserved through almost 60 million years of evolution and is shared only by primates, including humans - but no other known animal species.
Discovery may lead to powerful new therapy for asthma
University of Texas Medical Branch at Galveston researchers have found that a single enzyme is apparently critical to most allergen-provoked asthma attacks - and that activity of the enzyme, known as aldose reductase, can be significantly reduced by compounds that have already undergone clinical trials as treatments for complications of diabetes.
Abnormal Brain Circuits May Prevent Movement Disorder
Most people who carry a genetic mutation for a movement disorder called dystonia will never develop symptoms, a phenomenon that has puzzled scientists since the first genetic mutation was identified in the 1990's.
More Sepsis Current Events and Sepsis News Articles
 |
Sepsis and Non-infectious Systemic Inflammation: From Biology to Critical Care by Jean-Marc Cavaillon (Editor), Christophe Adrie (Editor) Providing definitions, clinical features and epidemiology, Sepsis and Non-infectious Systemic Inflammation adopts a comprehensive approach, describing in detail the various physiological systems involved. As such, this unique handbook and reference work is the first to combine sepsis and non-infectious SIRS, reviewing both the biological and medical aspects of these two important syndromes. The whole is rounded off with a discussion of past, present and future therapies. |
 |
Sepsis: New Strategies for Management by Jordi Rello (Editor), Marcos I. Restrepo (Editor) Sepsis is an important public health problem around the world. Severe sepsis carries significant morbidity, mortality and high costs. The incidence of sepsis is increasing because of the aging population, the growing number of immunocompromised hosts, the increasing use of invasive procedures, and, to a lesser extent, antibiotic resistance among pathogens. Despite recent advances in the pathogenesis, diagnosis, and therapeutic approaches the mortality rate associated with this condition remains high. Therefore, the goal of "Sepsis: New Strategies" is to review novel targets to be considered in patients with severe sepsis and to assess new developments for patients with sepsis originating in the respiratory tract. |
 |
Mechanisms of Sepsis-Induced Organ Dysfunction and Recovery (Update in Intensive Care Medicine) by Edward Abraham (Editor), Mervyn Singer (Editor) There have been tremendous advances in understanding the cellular mechanisms involved in sepsis and contributing to the development of multiple organ dysfunction and mortality in this setting. The chapters in this book provide up-to-date insights into important pathways that are initiated by sepsis. |
 |
Deep Sea Creatures by Monstrum Sepsis Monstrum Sepsis (Performer) Monstrum Sepsis emerges from the depths to bring you a new full length album of exquisitely inspired and arranged electronic music. Written and composed by Rob Wentz with additional instrumentation from Paul Karlik and guest vocals from Shikhee of Android Lust. Originally limited to 300 copies this new pressing features a few artwork enhancements as well as two new tracks. These 12 tracks will lift you off your feet in a sonic array of pulsing synthetics, disruptive modulations, sweeping strings and incredibly infectious rhythms. |
 |
Primordial Notions Delta 2001-2004 Monstrum Sepsis (Primary Contributor) |
|
Bacteria Sepsis: Video 1 of 3 [VHS] Starring: Diane Charsha | |
 |
Management of Sepsis: the PIRO Approach by Jordi Rello (Editor), Emili Díaz (Editor), Alejandro Rodríguez (Editor) Sepsis is a very important public health problem. It is widely acknowledged that the severe inflammatory response syndrome/severe sepsis paradigm fails to stratify sepsis patients adequately. This book reviews in detail how sepsis should be managed on the basis of a novel approach to staging. The PIRO (predisposing factors, infection, response, organ dysfunction) model was first proposed at the start of the decade on a theoretical basis and has now been translated into a practical approach for use at the bedside. It is loosely based on the TNM staging system for cancers, with points being allocated to each of the four aforementioned key characteristics of the septic process. The proposed PIRO framework facilitates evaluation of factors that are important in the pathogenesis of severe... |
 |
Sepsis (Competency-Based Critical Care) by Simon V. Baudouin (Editor) Sepsis is a serious medical condition, resulting from the immune response to a severe infection. Septicaemia is sepsis of the bloodstream caused by bactemeria, which is the presence of bacteria in the bloodstream. The term septecaemia is also used to refer to sepsis in general. In the US, sepsis is the leading cause of death in non-coronary ICU patients, and the tenth most common form of death overall. Sepsis is common and also more dangerous in the elderly, immunocompromised, and critically ill patients. It occurs in 1-2% of all hospitilizations and accounts for as much as 25% of all ICU bed utilization. It is a major cause of death in intensive care units worldwide, with mortality rates that range from 20% for sepsis to 40% for severe sepsis to more than 60% for septic shock. The... |
 |
Impact 1.5 250 ml Cans, 24/cs (202.8 oz/cs) by Novartis IMPACT 1.5 is a calorically dense, patented enteral formula containing arginine, dietary nucleotides and fish oil. Each member of the Impact family of products has a unique and patented formula that has been demonstrated in clinical trials to improve patient outcomes. Specifically, patients who received an Impact formula in clinical trials developed fewer infections and had shorter hospital stays than those patients fed enteral formulas. Impact 1.5 formula is intended for patients with fluid restrictions or high energy needs. Impact 1.5 is a Medical Food- consumers should consult with their physician on the use of this product. 250 ml Cans, 24/Case (202.8 oz/Case) Provides nutritional support for immuno compromised patients who require fluid restriction or have higher energy needs such... |
 |
Primordial Notions Gamma 1996-2000 Monstrum Sepsis (Primary Contributor) |
| © 2009 BrightSurf.com |